US10385018B2 - 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors - Google Patents
4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors Download PDFInfo
- Publication number
- US10385018B2 US10385018B2 US14/438,410 US201314438410A US10385018B2 US 10385018 B2 US10385018 B2 US 10385018B2 US 201314438410 A US201314438410 A US 201314438410A US 10385018 B2 US10385018 B2 US 10385018B2
- Authority
- US
- United States
- Prior art keywords
- dihydro
- oxo
- compound
- formula
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1=CC(C(N)=O)=C2C(=O)N(C[1*]C[2*])CC2=C1.C.C.C.C Chemical compound *C1=CC(C(N)=O)=C2C(=O)N(C[1*]C[2*])CC2=C1.C.C.C.C 0.000 description 15
- CPZFBGJDYPLHHM-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCCN3CCC4=C(C=CC=C4)C3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCCN3CCC4=C(C=CC=C4)C3)CC2=CC=C1 CPZFBGJDYPLHHM-UHFFFAOYSA-N 0.000 description 2
- BPLRYXJPQRMLEJ-UHFFFAOYSA-N CC1=CC(F)=CC(C)=C1C#N Chemical compound CC1=CC(F)=CC(C)=C1C#N BPLRYXJPQRMLEJ-UHFFFAOYSA-N 0.000 description 1
- PQYFAAZGSGZNGG-UHFFFAOYSA-N CC1=CC(F)=CC(C)=C1C(=O)O Chemical compound CC1=CC(F)=CC(C)=C1C(=O)O PQYFAAZGSGZNGG-UHFFFAOYSA-N 0.000 description 1
- BGXIIPLHTGBXQE-UHFFFAOYSA-N CC1=CC(F)=CC(C)=C1C(N)=O Chemical compound CC1=CC(F)=CC(C)=C1C(N)=O BGXIIPLHTGBXQE-UHFFFAOYSA-N 0.000 description 1
- MPNDLCBMLBACDD-UHFFFAOYSA-N CC1=CC(F)=CC(C)=C1N Chemical compound CC1=CC(F)=CC(C)=C1N MPNDLCBMLBACDD-UHFFFAOYSA-N 0.000 description 1
- KDXOONIQRUZGSY-UHFFFAOYSA-N CC1=CC(F)=CC=C1C(=O)O Chemical compound CC1=CC(F)=CC=C1C(=O)O KDXOONIQRUZGSY-UHFFFAOYSA-N 0.000 description 1
- KMHLGVTVACLEJE-UHFFFAOYSA-N CC1=CC(F)=CC=C1N Chemical compound CC1=CC(F)=CC=C1N KMHLGVTVACLEJE-UHFFFAOYSA-N 0.000 description 1
- QKSNNWPLGOKMHZ-UHFFFAOYSA-N CC1CCCC(C)N1CCCN1CC2=CC=CC(C(N)=O)=C2C1=O.Cl Chemical compound CC1CCCC(C)N1CCCN1CC2=CC=CC(C(N)=O)=C2C1=O.Cl QKSNNWPLGOKMHZ-UHFFFAOYSA-N 0.000 description 1
- QWUJLDJJCCLSKH-UHFFFAOYSA-N CN1CCN(CCCN2CC3=CC=CC(C(N)=O)=C3C2=O)CC1 Chemical compound CN1CCN(CCCN2CC3=CC=CC(C(N)=O)=C3C2=O)CC1 QWUJLDJJCCLSKH-UHFFFAOYSA-N 0.000 description 1
- VRBNZCUDGAWEMP-UHFFFAOYSA-N Cl.NC(=O)C1=C2C(=O)N(CCC3CCN(CC4=CC=CC=C4)CC3)CC2=CC=C1 Chemical compound Cl.NC(=O)C1=C2C(=O)N(CCC3CCN(CC4=CC=CC=C4)CC3)CC2=CC=C1 VRBNZCUDGAWEMP-UHFFFAOYSA-N 0.000 description 1
- GKALQNMQWUAENE-UHFFFAOYSA-N Cl.NC(=O)C1=C2C(=O)N(CCCN3CCCCC3)CC2=CC=C1 Chemical compound Cl.NC(=O)C1=C2C(=O)N(CCCN3CCCCC3)CC2=CC=C1 GKALQNMQWUAENE-UHFFFAOYSA-N 0.000 description 1
- FKYQTFXJWMLOJE-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(C4CCCCC4)CC3)CC2=CC(F)=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(C4CCCCC4)CC3)CC2=CC(F)=C1 FKYQTFXJWMLOJE-UHFFFAOYSA-N 0.000 description 1
- QBKPYKWJSWOHNY-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(C4CCCCC4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(C4CCCCC4)CC3)CC2=CC=C1 QBKPYKWJSWOHNY-UHFFFAOYSA-N 0.000 description 1
- JDUWWYRZYIZTIV-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(C4CCOCC4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(C4CCOCC4)CC3)CC2=CC=C1 JDUWWYRZYIZTIV-UHFFFAOYSA-N 0.000 description 1
- NBKCBJOAWBBQEW-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=CC=C4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=CC=C4)CC3)CC2=CC=C1 NBKCBJOAWBBQEW-UHFFFAOYSA-N 0.000 description 1
- RRKFGRBPRSLJIT-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=CN4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=CN4)CC3)CC2=CC=C1 RRKFGRBPRSLJIT-UHFFFAOYSA-N 0.000 description 1
- XEVOIPORGFHFTR-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=CO4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=CO4)CC3)CC2=CC=C1 XEVOIPORGFHFTR-UHFFFAOYSA-N 0.000 description 1
- VASLQBSSVPMGKR-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=CS4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=CS4)CC3)CC2=CC=C1 VASLQBSSVPMGKR-UHFFFAOYSA-N 0.000 description 1
- AOZCRPBUUBEYOW-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=NC=C4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(CC4=CC=NC=C4)CC3)CC2=CC=C1 AOZCRPBUUBEYOW-UHFFFAOYSA-N 0.000 description 1
- OVLKNUOJLKTKMD-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(CC4=CN=CC=C4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(CC4=CN=CC=C4)CC3)CC2=CC=C1 OVLKNUOJLKTKMD-UHFFFAOYSA-N 0.000 description 1
- HAPBLGPUQRBOCG-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(CC4=COC=C4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(CC4=COC=C4)CC3)CC2=CC=C1 HAPBLGPUQRBOCG-UHFFFAOYSA-N 0.000 description 1
- RBNSMVGFGNNHLH-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(CC4=CSC=C4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(CC4=CSC=C4)CC3)CC2=CC=C1 RBNSMVGFGNNHLH-UHFFFAOYSA-N 0.000 description 1
- CCGJVGSERDTSKY-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(C3CCN(CC4=NC=CC=C4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(C3CCN(CC4=NC=CC=C4)CC3)CC2=CC=C1 CCGJVGSERDTSKY-UHFFFAOYSA-N 0.000 description 1
- BDTIOERZNDWXLC-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CC3=CC=CC=C3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CC3=CC=CC=C3)CC2=CC=C1 BDTIOERZNDWXLC-UHFFFAOYSA-N 0.000 description 1
- QMFJNBILTNXCGW-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCC3=CC=CC=C3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCC3=CC=CC=C3)CC2=CC=C1 QMFJNBILTNXCGW-UHFFFAOYSA-N 0.000 description 1
- JDJQWPULECUFIA-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCC3=CC=CC=N3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCC3=CC=CC=N3)CC2=CC=C1 JDJQWPULECUFIA-UHFFFAOYSA-N 0.000 description 1
- JGWQDYTVDJMRNI-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCCC3=CC=CC=C3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCCC3=CC=CC=C3)CC2=CC=C1 JGWQDYTVDJMRNI-UHFFFAOYSA-N 0.000 description 1
- XURWTHPKVQLLQP-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCCN3CCC(CC4=CC=CC=C4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCCN3CCC(CC4=CC=CC=C4)CC3)CC2=CC=C1 XURWTHPKVQLLQP-UHFFFAOYSA-N 0.000 description 1
- IFYZHTOYLJQIFK-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCCN3CCC(N4CCCCC4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCCN3CCC(N4CCCCC4)CC3)CC2=CC=C1 IFYZHTOYLJQIFK-UHFFFAOYSA-N 0.000 description 1
- BLEKTFVHUNKMKI-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCCN3CCCC4=C3C=CC=C4)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCCN3CCCC4=C3C=CC=C4)CC2=CC=C1 BLEKTFVHUNKMKI-UHFFFAOYSA-N 0.000 description 1
- QUPVUNKXVXHSQT-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCCN3CCN(C4=CC=CC=C4)CC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCCN3CCN(C4=CC=CC=C4)CC3)CC2=CC=C1 QUPVUNKXVXHSQT-UHFFFAOYSA-N 0.000 description 1
- YYMORWAQDHOTFE-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCCN3CCOCC3)CC2=CC(F)=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCCN3CCOCC3)CC2=CC(F)=C1 YYMORWAQDHOTFE-UHFFFAOYSA-N 0.000 description 1
- FGRNZZFSZOJDGC-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCCN3CCOCC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCCN3CCOCC3)CC2=CC=C1 FGRNZZFSZOJDGC-UHFFFAOYSA-N 0.000 description 1
- UREAUZAZNZXBOS-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCN3CCC4=C(C=CC=C4)C3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCN3CCC4=C(C=CC=C4)C3)CC2=CC=C1 UREAUZAZNZXBOS-UHFFFAOYSA-N 0.000 description 1
- WGTJWDKKJAQXMI-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCN3CCCC4=C3C=CC=C4)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCN3CCCC4=C3C=CC=C4)CC2=CC=C1 WGTJWDKKJAQXMI-UHFFFAOYSA-N 0.000 description 1
- VWJCDLNJKREQPG-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCN3CCCCC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCN3CCCCC3)CC2=CC=C1 VWJCDLNJKREQPG-UHFFFAOYSA-N 0.000 description 1
- SDTLVPAVHMUAEM-UHFFFAOYSA-N NC(=O)C1=C2C(=O)N(CCN3CCOCC3)CC2=CC=C1 Chemical compound NC(=O)C1=C2C(=O)N(CCN3CCOCC3)CC2=CC=C1 SDTLVPAVHMUAEM-UHFFFAOYSA-N 0.000 description 1
- HYBBIBNJHNGZAN-UHFFFAOYSA-N O=CC1=CC=CO1 Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 1
- QLBOTMOXKJFQFU-MNYXATJNSA-N [3H]OC(=O)C1=C(C#N)C=C(F)C=C1C Chemical compound [3H]OC(=O)C1=C(C#N)C=C(F)C=C1C QLBOTMOXKJFQFU-MNYXATJNSA-N 0.000 description 1
- PQYFAAZGSGZNGG-MNYXATJNSA-N [3H]OC(=O)C1=C(C)C=C(F)C=C1C Chemical compound [3H]OC(=O)C1=C(C)C=C(F)C=C1C PQYFAAZGSGZNGG-MNYXATJNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12190130 | 2012-10-26 | ||
EP12190130.0 | 2012-10-26 | ||
EP12190130 | 2012-10-26 | ||
PCT/EP2013/072165 WO2014064149A1 (en) | 2012-10-26 | 2013-10-23 | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/072165 A-371-Of-International WO2014064149A1 (en) | 2012-10-26 | 2013-10-23 | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/460,438 Division US10800739B2 (en) | 2012-10-26 | 2019-07-02 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
US20150274662A1 US20150274662A1 (en) | 2015-10-01 |
US10385018B2 true US10385018B2 (en) | 2019-08-20 |
Family
ID=47115518
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/438,410 Active US10385018B2 (en) | 2012-10-26 | 2013-10-23 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors |
US16/460,438 Active US10800739B2 (en) | 2012-10-26 | 2019-07-02 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors |
US17/018,504 Active US11420940B2 (en) | 2012-10-26 | 2020-09-11 | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors |
US17/863,941 Active US11773064B2 (en) | 2012-10-26 | 2022-07-13 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/460,438 Active US10800739B2 (en) | 2012-10-26 | 2019-07-02 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors |
US17/018,504 Active US11420940B2 (en) | 2012-10-26 | 2020-09-11 | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors |
US17/863,941 Active US11773064B2 (en) | 2012-10-26 | 2022-07-13 | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors |
Country Status (19)
Country | Link |
---|---|
US (4) | US10385018B2 (pt) |
EP (1) | EP2912032B1 (pt) |
JP (1) | JP6314147B2 (pt) |
KR (1) | KR102221199B1 (pt) |
CN (1) | CN104768948B (pt) |
AU (1) | AU2013336725B2 (pt) |
BR (1) | BR112015009130B1 (pt) |
CA (1) | CA2889581C (pt) |
CL (1) | CL2015001020A1 (pt) |
DK (1) | DK2912032T3 (pt) |
EA (1) | EA028506B1 (pt) |
ES (1) | ES2813530T3 (pt) |
HK (1) | HK1212331A1 (pt) |
HU (1) | HUE051078T2 (pt) |
MX (1) | MX367425B (pt) |
PL (1) | PL2912032T3 (pt) |
PT (1) | PT2912032T (pt) |
SI (1) | SI2912032T1 (pt) |
WO (1) | WO2014064149A1 (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11420940B2 (en) | 2012-10-26 | 2022-08-23 | Nerviano Medical Sciences S.R.L. | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111100116A (zh) * | 2019-11-14 | 2020-05-05 | 南京大学 | 一类新型的含甲基吲哚的以吡唑啉为骨架的苯胺衍生物的制备方法及应用 |
CN111205263A (zh) * | 2020-04-22 | 2020-05-29 | 北京鑫开元医药科技有限公司 | 一种双环醇的制备方法及用途 |
WO2022225934A1 (en) | 2021-04-19 | 2022-10-27 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
US20230159525A1 (en) | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
US11939329B2 (en) | 2022-01-21 | 2024-03-26 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
TW202400596A (zh) | 2022-04-28 | 2024-01-01 | 美商辛瑟拉股份有限公司 | 三環parp1抑制劑及其用途 |
WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007047646A2 (en) | 2005-10-14 | 2007-04-26 | Janssen Pharmaceutica, N.V. | Substituted dihydro-isoindolones useful in treating kinase disorders |
US7232842B2 (en) | 2003-01-10 | 2007-06-19 | Board Of Trustees Of The Leland Stanford Junior University | Kinase inhibitors and associated pharmaceutical compositions and methods of use |
US20080108659A1 (en) | 2006-10-05 | 2008-05-08 | Gandhi Virajkumar B | Poly(adp-ribose)polymerase inhibitors |
WO2010133647A1 (en) | 2009-05-21 | 2010-11-25 | Nerviano Medical Sciences S.R.L. | Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors |
WO2011006794A1 (en) | 2009-07-14 | 2011-01-20 | Nerviano Medical Sciences S.R.L. | 3-oxo-2, 3-dihydro-lh-isoindole-4-carboxamides as parp inhibitors |
WO2011006803A1 (en) | 2009-07-14 | 2011-01-20 | Nerviano Medical Sciences S.R.L. | 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4929834B2 (ja) * | 2006-05-18 | 2012-05-09 | 富士通セミコンダクター株式会社 | ラッチ回路 |
CA2623257A1 (en) * | 2008-02-29 | 2009-08-29 | Scanimetrics Inc. | Method and apparatus for interrogating an electronic component |
KR102221199B1 (ko) | 2012-10-26 | 2021-03-04 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 선택적 parp-1 억제제로서의 4-카복스아미도-이소인돌리논 유도체 |
-
2013
- 2013-10-23 KR KR1020157013730A patent/KR102221199B1/ko active IP Right Grant
- 2013-10-23 PL PL13780358T patent/PL2912032T3/pl unknown
- 2013-10-23 AU AU2013336725A patent/AU2013336725B2/en active Active
- 2013-10-23 EP EP13780358.1A patent/EP2912032B1/en active Active
- 2013-10-23 US US14/438,410 patent/US10385018B2/en active Active
- 2013-10-23 PT PT137803581T patent/PT2912032T/pt unknown
- 2013-10-23 MX MX2015005245A patent/MX367425B/es active IP Right Grant
- 2013-10-23 HU HUE13780358A patent/HUE051078T2/hu unknown
- 2013-10-23 BR BR112015009130-0A patent/BR112015009130B1/pt active IP Right Grant
- 2013-10-23 JP JP2015538431A patent/JP6314147B2/ja active Active
- 2013-10-23 CA CA2889581A patent/CA2889581C/en active Active
- 2013-10-23 ES ES13780358T patent/ES2813530T3/es active Active
- 2013-10-23 WO PCT/EP2013/072165 patent/WO2014064149A1/en active Application Filing
- 2013-10-23 DK DK13780358.1T patent/DK2912032T3/da active
- 2013-10-23 SI SI201331777T patent/SI2912032T1/sl unknown
- 2013-10-23 EA EA201590820A patent/EA028506B1/ru not_active IP Right Cessation
- 2013-10-23 CN CN201380055668.XA patent/CN104768948B/zh active Active
-
2015
- 2015-04-22 CL CL2015001020A patent/CL2015001020A1/es unknown
-
2016
- 2016-01-07 HK HK16100120.5A patent/HK1212331A1/xx unknown
-
2019
- 2019-07-02 US US16/460,438 patent/US10800739B2/en active Active
-
2020
- 2020-09-11 US US17/018,504 patent/US11420940B2/en active Active
-
2022
- 2022-07-13 US US17/863,941 patent/US11773064B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7232842B2 (en) | 2003-01-10 | 2007-06-19 | Board Of Trustees Of The Leland Stanford Junior University | Kinase inhibitors and associated pharmaceutical compositions and methods of use |
WO2007047646A2 (en) | 2005-10-14 | 2007-04-26 | Janssen Pharmaceutica, N.V. | Substituted dihydro-isoindolones useful in treating kinase disorders |
US20080108659A1 (en) | 2006-10-05 | 2008-05-08 | Gandhi Virajkumar B | Poly(adp-ribose)polymerase inhibitors |
WO2010133647A1 (en) | 2009-05-21 | 2010-11-25 | Nerviano Medical Sciences S.R.L. | Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors |
WO2011006794A1 (en) | 2009-07-14 | 2011-01-20 | Nerviano Medical Sciences S.R.L. | 3-oxo-2, 3-dihydro-lh-isoindole-4-carboxamides as parp inhibitors |
WO2011006803A1 (en) | 2009-07-14 | 2011-01-20 | Nerviano Medical Sciences S.R.L. | 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition |
US8765972B2 (en) * | 2009-07-14 | 2014-07-01 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides with selective PARP-1 inhibition |
US8877944B2 (en) * | 2009-07-14 | 2014-11-04 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors |
Non-Patent Citations (6)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11420940B2 (en) | 2012-10-26 | 2022-08-23 | Nerviano Medical Sciences S.R.L. | 4-carboxamido-isoindolinone derivatives as selective parp-1 inhibitors |
US11773064B2 (en) | 2012-10-26 | 2023-10-03 | Nerviano Medical Sciences S.R.L. | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11773064B2 (en) | 4-carboxamido-isoindolinone derivatives as selective PARP-1 inhibitors | |
US8877944B2 (en) | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors | |
US8592416B2 (en) | Isoquinolin-1 (2H)-one derivatives as PARP-1 inhibitors | |
US8765972B2 (en) | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides with selective PARP-1 inhibition | |
US9073893B2 (en) | 3-Oxo-2,3-dihydro-1H-indazole-4-carboxamide derivatives as PARP-1 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NERVIANO MEDICAL SCIENCES S.R.L., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PAPEO, GIANLUCA MARIANO ENRICO;KRASAVIN, MIKHAIL YURIEVITCH;ORSINI, PAOLO;AND OTHERS;SIGNING DATES FROM 20150324 TO 20150410;REEL/FRAME:035491/0632 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |